145 related articles for article (PubMed ID: 9440741)
1. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pyrazoloacridine in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Res; 1991 Oct; 51(20):5467-70. PubMed ID: 1913666
[TBL] [Abstract][Full Text] [Related]
3. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
4. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
Erlichman C; Moore M; Kerr IG; Wong B; Eisenhauer E; Zee B; Whitfield LR
Cancer Res; 1991 Dec; 51(23 Pt 1):6317-22. PubMed ID: 1933893
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.
Bailey H; Kohler P; Tuttle R; Carbone PP; Hohneker JA; Clendeninn NJ; Wilding G
Invest New Drugs; 1992 Nov; 10(4):279-87. PubMed ID: 1487401
[TBL] [Abstract][Full Text] [Related]
7. Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.
Zimm S; Cleary SM; Horton CN; Howell SB
J Clin Oncol; 1988 Apr; 6(4):696-700. PubMed ID: 3357007
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.
Olver IN; Webster LK; Bishop JF; Stokes KH
Cancer Chemother Pharmacol; 1992; 29(5):354-60. PubMed ID: 1551173
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Bishop JF; Raghavan D; Olver IN; Reece P; Morris R; Friedlander ML
Cancer Chemother Pharmacol; 1989; 24(4):246-50. PubMed ID: 2526692
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Allegra CJ; Jenkins J; Weiss RB; Balis F; Drake JC; Brooks J; Thomas R; Curt GA
Invest New Drugs; 1990 May; 8(2):159-66. PubMed ID: 2143500
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
Do K; Wilsker D; Ji J; Zlott J; Freshwater T; Kinders RJ; Collins J; Chen AP; Doroshow JH; Kummar S
J Clin Oncol; 2015 Oct; 33(30):3409-15. PubMed ID: 25964244
[TBL] [Abstract][Full Text] [Related]
13. Crisnatol mesylate: phase I dose escalation by extending infusion duration.
Poplin EA; Chabot GG; Tuttle RL; Lucas S; Wargin WA; Baker LH
Invest New Drugs; 1991 Feb; 9(1):41-7. PubMed ID: 2026483
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.
Greidanus J; de Vries EG; Mulder NH; Sleijfer DT; Uges DR; Oosterhuis B; Willemse PH
J Clin Oncol; 1989 Jun; 7(6):790-7. PubMed ID: 2715807
[TBL] [Abstract][Full Text] [Related]
16. Phase I and clinical pharmacological evaluation of aphidicolin glycinate.
Sessa C; Zucchetti M; Davoli E; Califano R; Cavalli F; Frustaci S; Gumbrell L; Sulkes A; Winograd B; D'Incalci M
J Natl Cancer Inst; 1991 Aug; 83(16):1160-4. PubMed ID: 1886148
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Grochow LB; Noe DA; Dole GB; Rowinsky EK; Ettinger DS; Graham ML; McGuire WP; Donehower RC
J Natl Cancer Inst; 1989 Jan; 81(2):124-30. PubMed ID: 2909752
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.
Reece PA; Olver IN; Morris RG; Bishop JF; Guentert TW; Hill HS; Hillcoat BL
Cancer Chemother Pharmacol; 1990; 25(4):274-8. PubMed ID: 2136810
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Grochow LB; Noe DA; Ettinger DS; Donehower RC
Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Yamada Y; Yamamoto N; Shimoyama T; Horiike A; Fujisaka Y; Takayama K; Sakamoto T; Nishioka Y; Yasuda S; Tamura T
Cancer Sci; 2005 Oct; 96(10):721-8. PubMed ID: 16232205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
